No connection

Search Results

NRXS vs OKYO

NRXS
NeurAxis, Inc.
BEARISH
Price
$7.45
Market Cap
$85.7M
Sector
Healthcare
AI Confidence
90%
OKYO
OKYO Pharma Limited
BEARISH
Price
$1.65
Market Cap
$86.6M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
NRXS
--
OKYO
--
Forward P/E
NRXS
-248.33
OKYO
-8.25
P/B Ratio
NRXS
23.35
OKYO
-18.54
P/S Ratio
NRXS
24.01
OKYO
--
EV/EBITDA
NRXS
-11.04
OKYO
-9.5

Profitability

Gross Margin
NRXS
84.23%
OKYO
0.0%
Operating Margin
NRXS
-177.34%
OKYO
0.0%
Profit Margin
NRXS
-218.55%
OKYO
0.0%
ROE
NRXS
-285.36%
OKYO
--
ROA
NRXS
-80.63%
OKYO
-104.63%

Growth

Revenue Growth
NRXS
27.2%
OKYO
--
Earnings Growth
NRXS
--
OKYO
--

Financial Health

Debt/Equity
NRXS
0.13
OKYO
--
Current Ratio
NRXS
2.05
OKYO
0.58
Quick Ratio
NRXS
1.85
OKYO
0.53

Dividends

Dividend Yield
NRXS
--
OKYO
--
Payout Ratio
NRXS
0.0%
OKYO
0.0%

AI Verdict

NRXS BEARISH

NRXS exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of financial health metrics. While the stock has seen a speculative 217% price increase over the last year, this is completely disconnected from its fundamentals, as evidenced by a -218.55% profit margin and an extreme Price-to-Book ratio of 23.35. Despite moderate revenue growth and a strong current ratio, the company is destroying equity at an alarming rate (ROE -285.36%). The current valuation is unsustainable without a massive and immediate pivot to profitability.

Strengths
Strong Gross Margin (84.23%) suggesting high product value
Healthy liquidity with a Current Ratio of 2.05
Low Debt/Equity ratio (0.13) reducing immediate insolvency risk
Risks
Extreme operational losses (Profit Margin -218.55%)
Severe fundamental weakness (Piotroski F-Score 1/9)
Extreme valuation premiums (P/S 24.01, P/B 23.35)
OKYO BEARISH

OKYO exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity position. The company's negative Price/Book ratio (-18.54) and an ROA of -104.63% indicate significant insolvency risk and a lack of tangible asset backing. While analysts maintain a speculative target price of $8.00, the fundamental data reveals a company unable to cover short-term obligations (Current Ratio 0.58) with no current revenue stream. The disconnect between the bullish analyst target and the bearish deterministic health scores suggests a high-risk speculative play rather than a value investment.

Strengths
Significant upside potential if analyst target of $8.00 is realized
Positive 1-year price performance (+47.3%)
Operating in the high-growth Biotechnology sector
Risks
Severe liquidity crisis with a Current Ratio of 0.58
Negative shareholder equity as evidenced by Price/Book of -18.54
Critical financial health (Piotroski F-Score 2/9)

Compare Another Pair

NRXS vs OKYO: Head-to-Head Comparison

This page compares NeurAxis, Inc. (NRXS) and OKYO Pharma Limited (OKYO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile